- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07620340
AI-Supported Therapy for Depression and Anxiety Compared With Standard CBT
Evaluating the Efficacy of an AI Delivered, Neurosymbolic, Human Supervised Digital Intervention for Depression and Anxiety Versus Standard Cognitive Behavioural Therapy in Young Persons and Adults
This study is a pivotal, randomised, controlled, non-inferiority trial evaluating "Nook," an AI-delivered, neurosymbolic, clinician-supervised digital psychological intervention for depression and anxiety, compared with standard cognitive behavioural therapy (CBT). The trial will recruit 400 participants aged 16-64 years in the UK with moderate depression and/or anxiety symptoms. Participants will be randomised to receive either Nook or therapist-delivered CBT.
The primary objective is to determine whether Nook is non-inferior to CBT in reducing depression and anxiety symptoms, measured using the PHQ-9/PHQ-A and GAD-7 scales. Secondary outcomes include quality of life, functional impairment, sleep quality, treatment engagement, participant satisfaction, safety outcomes, and exploratory health economic measures.
The intervention incorporates clinician oversight and predefined escalation pathways for suicidality and clinical deterioration. Outcomes will be analysed using longitudinal mixed-effects models under an intention-to-treat framework.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Have symptoms of Generalized Anxiety Disorder (GAD) and/or symptoms of --•Major Depressive Disorder (MDD) as the primary reason for seeking treatment (formal diagnosis not required).(as determined by a Psychological Well-being Practitioner).
- Meet symptom-severity criteria on either validated screening measure:
- Depression: PHQ-9 (or PHQ-A for young persons) total score between 10 and 19, corresponding to moderate to moderately-severe symptoms, and/or
- Anxiety: GAD-7 total score between 8 and 21, corresponding to mild to severe symptoms.
- Aged 16-64 years
- If taking psychotropic medication for depression and/or anxiety, be on a stable regimen for at least 6 weeks prior to screening, with no initiation, discontinuation, or dose change during that period.
- Have reliable access to a compatible, internet-connected device and are able to use it for screening/eligibility, and the intervention and assessments (any potential costs to participants will be clearly noted in the PIS).
- Possess sufficient English language proficiency and cognitive capacity to engage with the digital therapeutic content and complete questionnaires.
- Provide informed consent.
- Willing to be randomised and to participate in a clinically-supervised CBT-based AI programme, including completion of scheduled outcome assessments.
Exclusion Criteria:
- Depression: PHQ-9 (or PHQ-A for young persons) total score >≥ 20
- Present with a primary or comorbid diagnosis (or history of) that is unsuitable for a digital CBT-based intervention (as judged by the Investigator), including:
- Post-traumatic stress disorder (PTSD) or complex trauma
- Psychotic disorder, bipolar disorder, and/or mania
- Complex or treatment-resistant obsessive-compulsive disorder (OCD)
- Personality disorder
- Eating disorder
- Substance or alcohol use disorder
- Exhibit high-risk clinical concerns, including:
- Current suicidal ideation with intent or plan (as indicated by PHQ-9 score and/or participant disclosure)
- Suicide attempt within the past 12 months
- Ongoing self-harming behaviours
- Requirement for urgent or crisis mental-health intervention (as indicated by •PHQ-9 score and/or participant disclosure)
- In participants aged 25 years and under, current treatment with an antidepressant medication initiated or dose-adjusted within the past 12 weeks (due to the recognised
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: CBT Comparator
Participants randomised to the comparator arm will receive standard cognitive behavioural therapy (CBT) delivered remotely by qualified CBT practitioners.
Therapy will be provided in accordance with routine evidence-based clinical practice, with participants undergoing the same assessment and safety monitoring schedule as the intervention arm.
|
A course of human delivered CBT by qualified therapists
|
|
Experimental: Nook
Description: Participants randomised to the intervention arm will receive access to Nook, a digitally delivered psychological intervention designed to support individuals experiencing symptoms of depression and anxiety.
The intervention is delivered remotely through a secure digital platform and incorporates structured therapeutic content alongside clinician oversight and safety monitoring procedures.
|
An AI-guided course of digital CBT with human clinician oversight
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patient Health Questionnaire - 9 items (PHQ-9)
Zeitfenster: Starting at Baseline, taken 3-weekly, to a 9 week end-point post-randomisation
|
A symptom measure of depression, ranging from 0 to 27. 27 being severe (high).
|
Starting at Baseline, taken 3-weekly, to a 9 week end-point post-randomisation
|
|
Patient Health Questionnaire - Adolescent (PHQ-A)
Zeitfenster: Starting at Baseline, taken 3-weekly, with a 9 week end-point post randomisation.
|
A symptom measure of depression for adolescents, ranging from 0 to 27. 27 being severe (high).
|
Starting at Baseline, taken 3-weekly, with a 9 week end-point post randomisation.
|
|
Generalized Anxiety Disorder assessment (GAD-7)
Zeitfenster: Starting at Baseline, taken 9-weekly, to a 9-week end point, post-randomisation
|
A symptom measure of anxiety, ranging from 0 to 21. 21 being severe (high).
|
Starting at Baseline, taken 9-weekly, to a 9-week end point, post-randomisation
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 369133
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Major Depression (MDD)
-
Yonggui YuanNoch keine RekrutierungMajor Depression (MDD)China
-
Daniel LindqvistLund University; KetabonRekrutierungMajor Depression (MDD)Schweden
-
King's College LondonCardiff and Vale University Health Board; South London and Maudsley NHS Foundation... und andere MitarbeiterRekrutierungMajor Depression (MDD)Vereinigtes Königreich
-
Supernus Pharmaceuticals, Inc.RekrutierungMajor Depression (MDD)Vereinigte Staaten
-
University of PennsylvaniaRekrutierung
-
Universidade Federal do Rio Grande do NorteFinanciadora de Estudos e ProjetosRekrutierungSuizidgedanken | Selbstmord | Schwere Depression | Major Depression (MDD) | MDDBrasilien
-
University of PretoriaNoch keine RekrutierungMajor Depression (MDD)Saudi-Arabien
-
Shanghai Mental Health CenterLingang National LaboratoryNoch keine RekrutierungMajor Depression (MDD
-
Tel Aviv UniversityNoch keine Rekrutierung
-
Sichuan Purity Pharmaceutical Technology Co., Ltd.Rekrutierung
Klinische Studien zur Cognitive Behavioural Therapy
-
CooperVision International Limited (CVIL)AbgeschlossenKurzsichtigkeitVereinigte Staaten
-
Karadeniz Technical UniversityAnmeldung auf Einladung
-
Children's Hospital Medical Center, CincinnatiAbgeschlossenIntraventrikuläre BlutungVereinigte Staaten
-
Columbia UniversityBeendet
-
Yuzuncu Yil UniversityRekrutierungFrühgeborene | Schlafqualität | Vitalfunktionen | NICU | İnfant Stress | SäuglingskomfortTürkei (türkiye)
-
University Hospital, GenevaAbgeschlossenAlpträume, REM-SchlaftypSchweiz
-
Hospital Clinic of BarcelonaRekrutierung
-
The Hong Kong Polytechnic UniversityChinese University of Hong Kong; University of DerbyNoch keine RekrutierungProstatakrebs | Kreativkunsttherapie
-
Chinese University of Hong KongRekrutierung
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)RekrutierungLatente TuberkuloseVereinigte Staaten